Nanoparticle-mediated interleukin-12 cancer gene therapy

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 3, 2010, Pages 472-485

  Hallaj Nezhadi, Somayeh ^a   Lotfipour, Farzaneh ^a,b   Dass, Crispin R ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ASIALOFETUIN; CHITOSAN; CHLOESTERYL CHLOROFORMATE; CHOLESTEROL; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; METHOXYPOLYETHYLENEGLYCOL; NANOPARTICLE; PACLITAXEL; PLASMID DNA; POLY(N METHYLDIETHENEAMINE SEBACATE); POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; POLY[ALPHA(4 AMINOBUTYL) LEVO GLYCOLIC ACID]; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; WATER SOLUBLE LIPOPOLYMER;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CARCINOMA; BREAST CARCINOMA; BREAST TUMOR; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CARCINOMA; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; ENCAPSULATION; FIBROSARCOMA; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY CARCINOMA; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LYMPHOMA; MELANOMA; MELANOMA B16; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PATIENT SAFETY; RETICULOSARCOMA; REVIEW; SARCOMA; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS TISSUE TUMOR; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; ZETA POTENTIAL;

EID: 78650402481     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3630v     Document Type: Review

References (77)

1. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell. 2004 Nov;6(5):433-8.
2. Habib NA. Cancer Gene Therapy Past Achievements and Future Challenges. New York: Kluwer Academic Publishers; 2000.
3. David T. Curiel, Douglas JT. Cancer Gene Therapy. Totowa, NJ: Humana Press Inc.; 2005
4. Vitolo D, Letessier EM, Johnson JT, Whiteside TL. Immunologic effector cells in head and neck cancer. J Natl Cancer Inst Monogr. 1992(13):203-208.
5. Cortesina G, De Stefani A, Sacchi M, Rosso S, Galeazzi E. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck. 1993 May-Jun;15(3):266-270.
6. Thomson AW, Lotze MT. The Cytokine Handbook. 4th ed. London: Academic Press; 2003.
7. Kresina TF. An Introduction to Molecular Medicine and Gene Therapy. New York: A JOHN WILEY & SONS, INC.; 2001.
8. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993 Oct 1;178(4):1223-1230.
9. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol. 2002 Apr;13(2):128-131.
10. Schmidt-Wolf GD, Schmidt-Wolf IG. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med. 2003 Feb;9(2):67-72.
11. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother. 2004 Apr;58(3):168-172.
12. Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine. 2007;2(3):353-360.
13. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004 Sep 30;113(1-3):151-170.
14. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001 Mar 23;47(1):3-19.
15. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang NS. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther. 1997 Jul 20;8(11):1303-1311.
16. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999 Mar 20;10(5):697-709.
17. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-2213.
18. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6291-6296.
19. Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, Yang NS. Gene gunmediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother. 1999 Mar;22(2):135-144.
20. Dow SW, Elmslie RE, Fradkin LG, Liggitt DH, Heath TD, Willson AP, et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther. 1999 Dec 10;10(18):2961-2972.
21. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 1999 Nov;6(11):1867-1875.
22. Blezinger P, Freimark BD, Matar M, Wilson E, Singhal A, Min W, et al. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther. 1999 Mar 20;10(5):723-731.
23. Chen W, Shao CS, Shen JG, Pan Y, Zheng S. [Therapeutic effect of cationic liposome-mediated interleukin-12 gene delivery on murine melanoma in vivo]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2005 Jan;34(1):73-76.
24. Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology. 2005 Aug;66(2):461-466.
25. Faneca H, Cabrita AS, Simoes S, Pedroso de Lima MC. Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system. Biochim Biophys Acta. 2007 May;1768(5):1093-1102.
26. Speroni L, Gasparri J, de los ABV, Chiaramoni NS, Smagur A, Szala S, et al. Antitumoral effect of IL-12 gene transfected via liposomes into B16F0 cells. Acta Biochim Pol. 2009;56(2):249-253.
27. Harada N, Shimada M, Okano S, Suehiro T, Soejima Y, Tomita Y, et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol. 2004 Dec 1;173(11):6635-6644.
28. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20;26(36):5896-5903.
29. Zhu S, Li S. Systemic IL-12 gene therapy for treating malignancy via intramuscular electroporation. Methods Mol Biol. 2008;423:327-337.
30. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol. 2001;79:55-92.
31. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002 Apr;13(2):155-168.
32. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995 Jan 1;154(1):116-127.
33. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des. 2003;9(24):1981-1991.
34. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 1996 Aug 1;184(2):741-746.
35. Skeen MJ, Miller MA, Shinnick TM, Ziegler HK. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J Immunol. 1996 Feb 1;156(3):1196-1206.
36. Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer. 2004 Apr 20;109(4):499-506.
37. Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods. 1999 Sep;19(1):114-120.
38. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol. 1996 Feb 1;156(3):1095-1100.
39. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2219-2223.
40. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol. 1996 May 1;156(9):3357-3365.
41. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med. 2009;7:5.
42. Siddiqui F, Ehrhart EJ, Charles B, Chubb L, Li CY, Zhang X, et al. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia. 2006 Nov;22(7):587-606.
43. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res. 2000 Feb 15;60(4):1111-1116.
44. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995 Apr 19;87(8):581-586.
45. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol. 1996; 38 Suppl: S16-S21.
46. Davidoff AM, Kimbrough SA, Ng CY, Shochat SJ, Vanin EF. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. Journal of pediatric surgery. 1999 May;34(5):902-906; discussion 6-7.
47. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, 3rd, McKinney TG, Schreiber RD, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995 Jun 15;154(12):6466-6474.
48. Fallarino F, Ashikari A, Boon T, Gajewski TF. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. International immunology. 1997 Sep;9(9):1259-1269.
49. Barker SE, Grosse SM, Siapati EK, Kritz A, Kinnon C, Thrasher AJ, et al. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. British journal of cancer. 2007 Jul 16;97(2):210-217.
50. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T celldependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2475-2480.
51. Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8591-8596.
52. Siapati KE, Barker S, Kinnon C, Michalski A, Anderson R, Brickell P, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. British journal of cancer. 2003 May 19;88(10):1641-1648.
53. Croce M, Meazza R, Orengo AM, Radic L, De Giovanni B, Gambini C, et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):735-742.
54. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther. 2001 Apr 10;12(6):671-684.
55. Miller G, Lahrs S, Dematteo RP. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2003 Apr;17(6):728-730.
56. Shimizu T, Berhanu A, Redlinger RE, Jr., Watkins S, Lotze MT, Barksdale EM, Jr. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. Journal of pediatric surgery. 2001 Aug;36(8):1285-1292.
57. Iinuma H, Okinaga K, Fukushima R, Inaba T, Iwasaki K, Okinaga A, et al. Superior protective and therapeutic effects of IL-12 and IL-18 genetransduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol. 2006 Mar 15;176(6):3461-3469.
58. Koido S, Hara E, Homma S, Namiki Y, Ohkusa T, Gong J, et al. Cancer vaccine by fusions of dendritic and cancer cells. Clinical & developmental immunology. 2009;2009:657369.
59. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med. 1995 Mar 1;181(3):901-914.
60. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997 Oct 1;90(7):2541-2548.
61. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997 Mar;3(3):409-417.
62. Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J Control Release. 2003 Feb 21;87(1-3):177-186.
63. Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE, Yang NS, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 1996 Aug 1;56(15):3399-3403.
64. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol. 1999 Jan-Feb;27(1):58-63.
65. Maheshwari A, Mahato RI, McGregor J, Han S, Samlowski WE, Park JS, et al. Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol Ther. 2000 Aug;2(2):121-130.
66. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther. 2001 Aug;4(2):130-138.
67. Fewell JG, Matar M, Slobodkin G, Han SO, Rice J, Hovanes B, et al. Synthesis and application of a nonviral gene delivery system for immunogene therapy of cancer. J Control Release. 2005 Dec 5;109(1-3):288-298.
68. Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, et al. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med. 2009 Aug;11(8):718-728.
69. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998 Oct;153(4):1249-1256.
70. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-6971.
71. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Codelivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006 Oct;5(10):791-796.
72. Kim TH, Jin H, Kim HW, Cho MH, Cho CS. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther. 2006 Jul;5(7):1723-1732.
73. Diez S, Navarro G, de ICT. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med. 2009 Jan;11(1):38-45.
74. Diez S, Migueliz I, Tros de Ilarduya C. Targeted cationic poly(D,L-lactic-co-glycolic acid) nanoparticles for gene delivery to cultured cells. Cell Mol Biol Lett. 2009;14(2):347-362.
75. Rodrigo-Garzon M, Berraondo P, Ochoa L, Zulueta JJ, Gonzalez-Aseguinolaza G. Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. Cancer Gene Ther. 2010 Jan;17(1):20-27.
76. Ogris M. Nucleic acid based therapeutics for tumor therapy. Anticancer Agents Med Chem. 2006 Nov;6(6):563-570.
77. Ogris M, Wagner E. Tumor-targeted gene transfer with DNA polyplexes. Somat Cell Mol Genet. 2002 Nov;27(1-6):85-95.